Ayna joins Antag with extensive experience in obesity and clinical pharmacology. She most recently served as Senior Principal Clinical Pharmacology Scientist at Novo Nordisk, having led several global ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Shares of Novo Nordisk A/S (NVO) climbed 0.4% on Monday and rose in extended trading after the Danish drugmaker said it had ...

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

which will enable us to meet both current and future demand for innovative medicines worldwide,” said Novo Nordisk’s executive vice president of chemistry, production, control & product supply ...

In this exclusive interview, Business Today speaks with Vikrant Shrotriya, Managing Director of Novo Nordisk India, about the significance of semaglutide (the active ingredient in Wegovy), its ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

control and product supply at Novo Nordisk, said in a statement. Brazil, where Novo has been present since 1990, represents one of the Danish drugmaker’s five biggest markets, Reuters reported ...

Novo Nordisk A/S has a fifty-two week low of $60.61 and a fifty-two week high of $148.15. The company has a market capitalization of $285.03 billion, a price-to-earnings ratio of 19.31, a P/E/G ...

SAO PAULO, April 7 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost ...

In its fourth quarter 2024 investor letter, Artisan Global Opportunities Fund emphasized stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and ...